Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 3/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816620 | 0.93 | PRKCQ (0.58) | PRKCQMAPTAPPTDP1KMT2A | |
| SCHEMBL4482286 | 0.92 | KMT2A (0.45) | PRKCQMAPTAPPTDP1KMT2A | |
| SCHEMBL4479093 | 0.90 | PRKCQ (0.46) | PRKCQMAPTTDP1KMT2AATM | |
| SCHEMBL4478175 | 0.89 | MAPT (0.51) | PRKCQMAPTTDP1KMT2ABLM | |
| SCHEMBL4490167 | 0.89 | KMT2A (0.53) | PRKCQMAPTAPPTDP1KMT2A | |
| SCHEMBL4468391 | 0.89 | MAPT (0.46) | PRKCQMAPTAPPTDP1KMT2A | |
| SCHEMBL4475566 | 0.88 | MAPT (0.60) | PRKCQMAPTTDP1KMT2ABLM | |
| SCHEMBL4476078 | 0.87 | LMNA (0.46) | PRKCQMAPTTDP1KMT2ABLM | |
| SCHEMBL4479865 | 0.87 | PKM (0.43) | PRKCQMAPTTDP1KMT2AATM | |
| SCHEMBL4485111 | 0.86 | MAPT (0.44) | PRKCQMAPTTDP1KMT2ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | PRKCQ 2/4885MAPT 3483/4885APP 1211/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | PRKCQ 2/4885MAPT 3483/4885APP 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.